Aurobac Therapeutics presents strategy and growing pipeline​ to tackle severe infections and antimicrobial resistance

• AUROBAC’s R&D strategy focuses on the high unmet medical needs associated with infections in acute hospital settings, amidst the growing antimicrobial resistance (AMR) epidemic. It aims to tackle both the causes and consequences of potentially life-threatening bacterial infections and AMR, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) and sepsis.
• Boehringer Ingelheim’s participation in AUROBAC is part of a wider pandemic preparedness initiative, which includes a EUR 50 million investment in the AMR action fund by Boehringer Ingelheim as part of a total planned investment of EUR 200 million in partnerships to specifically combat emerging infectious diseases.
• Boehringer Ingelheim’s Venture Fund is planning to invest in up to 10 AMR infection companies.
• AUROBAC is progressing a growing discovery and early pre-clinical pipeline:
• ATX101 is the newest addition to the pipeline and will be developed as a potential first-in-class treatment for septic shock in collaboration with Boehringer Ingelheim. It is planned to be moved into clinical development in 2025. ATX101 has emerged from Boehringer Ingelheim’s Research Beyond Borders (RBB) initiative. RBB was established to explore disruptive ideas and emerging science for and beyond Boehringer Ingelheim’s core research scope in collaboration with partners across the world.  
• ATX401 (formerly CF-370) is the first engineered lysin with potent in vitro activity against multiple clinically relevant Gram-negative bacteria. It is currently being progressed in pre-clinical research.  
• AUROBAC has joined forces with GENERARE Bioscience to leverage their DNA-guided synthetic biology platform for the discovery of novel drug leads of microbial origin

Why it matters

The increase in AMR infections is a looming global crisis, resulting in about 1.27 million casualties globally every year and it has been estimated that by 2050, as many as 10 million people could die per year from bacterial infections caused by AMR strains, making it potentially deadlier than cancer.

AUROBAC brings together the world leading expertise of Evotec in infectious diseases research, bioMérieux’s market-leading expertise in infectious disease diagnostics and Boehringer Ingelheim’s broad drug discovery and significant clinical development capabilities with its own expertise and capabilities and individual partnered projects.

Paola Casarosa, Member of the Board of Managing Directors with responsibility the Innovation Unit:

“Life-threatening infectious diseases are considered among the biggest emerging health threats globally. This is why we are committed to advancing innovative new ways to address this threat. We are delighted about AUROBAC’s progress and about being able to contribute to their pipeline with a novel approach to treat septic shock, a severe consequence of infections.”

Martin Everett, AUROBAC Chief Scientific Officer:

“With AMR recognized by WHO as one of the foremost global public health threats, there is an urgent and unmet need for new therapies to prevent the deadly consequences of Gram-negative resistant infections in acute hospital settings. Our diagnostic-driven strategy and innovative pipeline underscore our dedication to developing a new generation of precision drugs and improving outcomes for patients in urgent need.”

More info:

AUROBAC THERAPEUTICS: Presentation of our R&D Strategy and Pipeline

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com    

About Boehringer Ingelheim Venture Fund  

Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in ground-breaking companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. For more information, please visit: www.boehringer-ingelheim-venture.com  

Boehringer Ingelheim’s Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.